Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (29)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Filizola, M.
Right arrow Articles by loew, G. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Filizola, M.
Right arrow Articles by loew, G. H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Protein Engineering, Vol. 12, No. 11, 927-942, November 1999
© 1999 Oxford University Press

3D modeling, ligand binding and activation studies of the cloned mouse {delta}, µ and {kappa} opioid receptors

Marta Filizola1, Liisa Laakkonen1 and Gilda H. loew2

Molecular Research Institute, 2495 Old Middlefield Way, Mountain View, CA 94043, USA 1 These two authors contributed equally to the work described

Refined 3D models of the transmembrane domains of the cloned {delta}, µ and {kappa} opioid receptors belonging to the superfamily of G-protein coupled receptors (GPCRs) were constructed from a multiple sequence alignment using the alpha carbon template of rhodopsin recently reported. Other key steps in the procedure were relaxation of the 3D helix bundle by unconstrained energy optimization and assessment of the stability of the structure by performing unconstrained molecular dynamics simulations of the energy optimized structure. The results were stable ligand-free models of the TM domains of the three opioid receptors. The ligand-free {delta} receptor was then used to develop a systematic and reliable procedure to identify and assess putative binding sites that would be suitable for similar investigation of the other two receptors and GPCRs in general. To this end, a non-selective, `universal' antagonist, naltrexone, and agonist, etorphine, were used as probes. These ligands were first docked in all sites of the model {delta} opioid receptor which were sterically accessible and to which the protonated amine of the ligands could be anchored to a complementary proton-accepting residue. Using these criteria, nine ligand–receptor complexes with different binding pockets were identified and refined by energy minimization. The properties of all these possible ligand–substrate complexes were then examined for consistency with known experimental results of mutations in both opioid and other GPCRs. Using this procedure, the lowest energy agonist–receptor and antagonist–receptor complexes consistent with these experimental results were identified. These complexes were then used to probe the mechanism of receptor activation by identifying differences in receptor conformation between the agonist and the antagonist complex during unconstrained dynamics simulation. The results lent support to a possible activation mechanism of the mouse {delta} opioid receptor similar to that recently proposed for several other GPCRs. They also allowed the selection of candidate sites for future mutagenesis experiments.

Keywords: G-protein coupled receptors/ligand binding site/opioid receptors/transmembrane helices

2 To whom correspondence should be addressed. E-mail: loew{at}montara.molres.org


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
D. Townsend IV, P. S. Portoghese, and D. R. Brown
Characterization of Specific Opioid Binding Sites in Neural Membranes from the Myenteric Plexus of Porcine Small Intestine
J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 385 - 393.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. Pil and J. Tytgat
Serine 329 of the {micro}-Opioid Receptor Interacts Differently with Agonists
J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 924 - 930.
[Abstract] [Full Text] [PDF]


Home page
Protein Eng Des SelHome page
C. M. Topham, L. Mouledous, and J.-C. Meunier
On the spatial disposition of the fifth transmembrane helix and the structural integrity of the transmembrane binding site in the opioid and ORL1 G protein-coupled receptor family
Protein Eng. Des. Sel., July 1, 2000; 13(7): 477 - 490.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.